SCHEMBL736202

SCHEMBL736202

C#Cc1ccnc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.50
LOXL2 Q9Y4K0 1/20 0.47
HTR1A P08908 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
MAPT P10636 4/20 0.43
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
CYP1A2 P05177 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30098629 1.00 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL738596 0.86 MAPT (0.52) NCF1LOXL2MAPTKDM4EALDH1A1
SCHEMBL28307763 0.85 NCF1 (0.39) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL15947627 0.83 NCF1 (0.54) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL21858489 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL6102087 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL1160101 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL3090736 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL828123 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL29619912 0.79 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115650816-A Method for synthesizing 1, 3-diacetylene compound through heterogeneous catalysis 成都理工大学 2023-01-31 CN claimed
CN-111518117-B 1, 2-oxazinopyran compound and preparation method and application thereof 西安凯新生物科技有限公司 2022-08-26 CN claimed
CN-111518117-A 1, 2-oxazinopyran compound and preparation method and application thereof 朱翠萍 2020-08-11 CN claimed
CN-119350362-A Condensed ring organic compounds and their use in organic electronic devices 广州追光科技有限公司 2025-01-24 CN disclosed
CN-117164492-A Organic semiconductor g-C 3 N 4 Method for catalytic synthesis of (E) -vinyl selenone compound 化学与精细化工广东省实验室 2023-12-05 CN disclosed
CN-111518117-B 1, 2-oxazinopyran compound and preparation method and application thereof 西安凯新生物科技有限公司 2022-08-26 CN disclosed
CN-110627610-B Method for synthesizing alkyne by catalyzing asymmetric cross coupling 南方科技大学 2022-07-05 CN disclosed
CN-112939982-A Alkyne heterocyclic BTK inhibitor and preparation method and application thereof 药雅科技(上海)有限公司 2021-06-11 CN disclosed
CN-111662313-A Temperature-controlled molecular motor photoelectric material, preparation method and application 南京邮电大学 2020-09-15 CN disclosed
CN-111518117-A 1, 2-oxazinopyran compound and preparation method and application thereof 朱翠萍 2020-08-11 CN disclosed
CN-105408340-B Tylosin derivatives and process for their preparation 拜耳动物保健有限责任公司 2020-06-12 CN disclosed
US-20160108077-A1 TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF THE KITASAKO INSTITUTE (JP) 2016-04-21 US disclosed
EP-2999707-A1 TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF Bayer Animal Health GmbH (DE) 2016-03-30 EP disclosed
CN-105408340-A Tylosin derivatives and method for preparation thereof BAYER ANIMAL HEALTH GMBH 2016-03-16 CN disclosed
EP-1847545-B1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME UBE INDUSTRIES (JP) 2013-03-06 EP disclosed
CN-101111499-B Substituted ethynyl gold-nitrogen-containing heterocyclic carbene complex and organic electroluminescent device using the same UBE INDUSTRIES 2012-05-23 CN disclosed
US-8137821-B2 Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same UBE INDUSTRIES, LTD. (JP) 2012-03-20 US disclosed
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same UBE INDUSTRIES, LTD. (JP) 2009-04-09 US disclosed
CN-101111499-A Substituted ethynyl gold-nitrogenated heterocyclic carbene complex and organic electroluminescent device using same UBE INDUSTRIES (JP) 2008-01-23 CN disclosed
EP-1847545-A1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME Ube Industries, Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108077-A1 TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF TMSB10, MLN, TMSB4X NCF1 2364/4885LOXL2 794/4885HTR1A 1630/4885
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same ACSL3, ATXN2L, ACSL1 NCF1 360/4885LOXL2 135/4885HTR1A 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.